undamentalytics Newsletter
Sign in

4d Molecular Therapeutics, Inc. balance sheet

At the end of fiscal 2025, 4d Molecular Therapeutics, Inc. had total assets of $567m, total liabilities of $61.0m and shareholders' equity of $506m. It held $60.2m in cash against $0 of debt: net cash of $60.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents50277153522491496070
Receivables1100————
Total current assets53283256221297435413383
Total assets58288353262340560567493
Accounts payable2253441113
Deferred revenue (current)67310000
Total current liabilities1317161619294448
Long-term debt——————020
Total debt000000020
Total liabilities2832343132506185
Shareholders' equity−73256319231308511506408
Non-controlling interests and other (assets − liabilities − equity)103———————
Net debt (negative = net cash)−50−277−153−52−249−149−60−51
Shares outstanding5m—32m33m43m46m58m55m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: FDMT vs VSTMAGIO vs FDMTFDMT vs SEPN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from 4d Molecular Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 4d Molecular Therapeutics, Inc.